Dogra S C, May B K
Department of Biochemistry, University of Adelaide, South Australia, Australia.
Arch Biochem Biophys. 1996 Mar 15;327(2):271-8. doi: 10.1006/abbi.1996.0121.
The phenobarbital-induced activation of cytochrome P4502H1 (CYP2H1) and 5-aminolevulinate synthase (ALAS-1) genes in chick embryo hepatocytes occurs at the level of gene transcription, but the molecular mechanism underlying this induction is not understood in detail. In the present study, we report that the protein kinase inhibitor 2-aminopurine markedly inhibits the phenobarbital-induced activation of CYP2H1 and ALAS-1 genes as measured by Northern blot analysis, but does not alter the basal expression of these genes in the absence of drug. Transient expression studies confirmed these findings. The construct pCATBg4.8 contains a 4.8-kb drug-responsive domain of the CYP2H1 gene fused to the enhancerless SV40 promoter and the drug-induced expression of this construct in chick embryo hepatocytes was inhibited by 2-aminopurine. Another construct pCAT, with the first 547 bp of 5' flanking region of the CYP2H1 gene, is not responsive to drug and basal expression of this construct was not altered by the addition of 2-aminopurine. The evidence presented here demonstrates that the inhibitory action of 2-aminopurine on drug-induction is not due to a toxic effect on the cells. The induction of the CYP2H1 gene by phenobarbital was not altered by treating cells with the specific inhibitors for protein kinase C (GF 109203X and Ro 31-8220) or prolonged exposure to 12-O-tetradecanoyl-phorbol 13-acetate (TPA) or treatment with the specific inhibitors for tyrosine kinase (genistein and tyrphostin A25). Overall, the data indicate that a 2-amino-purine-sensitive protein kinase activity is required for the phenobarbital-induction mechanism but this is unlikely to be a protein kinase C or tyrosine kinase. It can be postulated that phosphorylation of a drug receptor protein may be an important step in the drug-induction process.
苯巴比妥诱导鸡胚肝细胞中细胞色素P4502H1(CYP2H1)和5-氨基酮戊酸合酶(ALAS-1)基因的激活发生在基因转录水平,但这种诱导作用背后的分子机制尚未完全清楚。在本研究中,我们报告蛋白质激酶抑制剂2-氨基嘌呤通过Northern印迹分析显著抑制苯巴比妥诱导的CYP2H1和ALAS-1基因的激活,但在无药物情况下不改变这些基因的基础表达。瞬时表达研究证实了这些发现。构建体pCATBg4.8包含与无增强子的SV40启动子融合的CYP2H1基因的4.8 kb药物反应结构域,2-氨基嘌呤抑制该构建体在鸡胚肝细胞中的药物诱导表达。另一个构建体pCAT含有CYP2H1基因5'侧翼区的前547 bp,对药物无反应,添加2-氨基嘌呤也不改变该构建体的基础表达。此处提供的证据表明,2-氨基嘌呤对药物诱导的抑制作用并非由于对细胞的毒性作用。用蛋白激酶C的特异性抑制剂(GF 109203X和Ro 31-8220)处理细胞、长时间暴露于12-O-十四烷酰佛波醇13-乙酸酯(TPA)或用酪氨酸激酶的特异性抑制剂(染料木黄酮和 tyrphostin A25)处理均不改变苯巴比妥对CYP2H1基因的诱导作用。总体而言,数据表明苯巴比妥诱导机制需要2-氨基嘌呤敏感的蛋白激酶活性,但这不太可能是蛋白激酶C或酪氨酸激酶。可以推测,药物受体蛋白的磷酸化可能是药物诱导过程中的一个重要步骤。